SCHEDULE: Kynam Capital Management Discloses Celldex Stake

Kynam Capital Management, LP, along with its GP and principal Yue Tang, has reported a 6.78% beneficial ownership of Celldex Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have jointly filed a Schedule 13G, indicating a significant beneficial ownership in Celldex Therapeutics, Inc.
• The filing, dated June 30, 2026, reports a 6.78% ownership stake in Celldex Therapeutics, Inc. common stock.
• The reporting persons collectively hold 5,322,908 shares, with shared voting and dispositive power.
• No single reporting person holds sole voting or dispositive power over any shares.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but stable ownership stake without immediate aggressive action implied.

Positives

• Kynam Capital Management has established a notable 6.78% stake in Celldex Therapeutics, Inc., signaling confidence in the company's prospects.
• The filing indicates a substantial investment of 5,322,908 shares, representing a significant commitment.

Negatives

• The reporting persons hold 0 shares with sole voting or dispositive power, indicating a distributed control structure.
• The filing does not provide specific details on the acquisition cost or strategy behind the investment.

Risks

• While not explicitly stated as a risk in this filing, significant ownership by investment firms can sometimes lead to activist investor campaigns if performance does not meet expectations.
• The shared voting and dispositive power structure could lead to slower decision-making processes if consensus is not reached among the reporting persons.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance from Celldex Therapeutics. It solely reports on the ownership stake of Kynam Capital Management.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant ownership filings like this Schedule 13G are common in the biotechnology sector, where institutional investors often take substantial stakes in companies with promising pipelines. This filing places Kynam Capital Management as a notable shareholder in Celldex Therapeutics.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest in Celldex Therapeutics, potentially influencing market perception and stock price.
• Management of Celldex Therapeutics: The significant stake held by Kynam Capital Management may warrant engagement or communication regarding company strategy.

Next Steps

• Kynam Capital Management will continue to hold and potentially manage its stake in Celldex Therapeutics.
• Celldex Therapeutics will continue its operations and report its financial and operational results in subsequent filings.

Key Dates

Keywords

Celldex Therapeutics, Kynam Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Hampton, New Jersey